Compare EHI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | DTIL |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 197.9M |
| IPO Year | 2003 | 2019 |
| Metric | EHI | DTIL |
|---|---|---|
| Price | $5.42 | $6.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 162.6K | ★ 230.4K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $3.53 |
| 52 Week High | $6.61 | $9.62 |
| Indicator | EHI | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 27.91 | 32.87 |
| Support Level | N/A | $6.02 |
| Resistance Level | $6.03 | $7.65 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 20.31 | 8.70 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).